BOLT

News Bolt Biotherapeutics faces Nasdaq delisting risk By Investing.com - Investing.com Australia

14d ago

News Bolt Biotherapeutics GAAP EPS of -$4.31 misses by $1.46, revenue of $0.03M misses by $1.47M

20d ago

SEC filing BOLT Reports $2.5M Q4 Rev, $7.7M FY Rev, $31.8M Cash, $5.0M Q4 R&D, $28.5M FY R&D, BDC-4182 Phase 1 Data 3Q2026

81d ago

Insider trade Purchase by William P. Quinn (President, CEO and CFO)

104d ago

Insider trade Purchase by Sarah Nemec (Senior VP, Finance and PAO)

104d ago

Scanner Unusual volume (7.8x average)

124d ago